Biogen   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Geneva Switzerland (1978)
Status: Acquired by Biogen-IDEC (2003)

Organization Overview

First Clinical Trial
1995
NCT00168740
First Marketed Drug
1996
interferon beta-1b (betaseron)
First NDA Approval
2003
alefacept (Amevive)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biogen | BIOGEN | BIOGEN INC | Bioverativ (Biogen)